For: | Péntek M, Lakatos PL, Oorsprong T, Gulácsi L, Pavlova M, Groot W, Rencz F, Brodszky V, Baji P, Crohn’s Disease Research Group. Access to biologicals in Crohn’s disease in ten European countries. World J Gastroenterol 2017; 23(34): 6294-6305 [PMID: 28974896 DOI: 10.3748/wjg.v23.i34.6294] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v23/i34/6294.htm |
Number | Citing Articles |
1 |
Johan Burisch. Long‐term disease course, cost and prognosis of inflammatory bowel disease: epidemiological studies of a European and a Danish inception cohort. APMIS 2023; 131(S147): 1 doi: 10.1111/apm.13334
|
2 |
Hasumati Rahalkar, Alan Sheppard, Sam Salek. Biosimilar development and review process in the BRICS-TM countries: Proposal for a standardized model to improve regulatory performance. Expert Review of Clinical Pharmacology 2022; 15(2): 215 doi: 10.1080/17512433.2022.2034498
|
3 |
Zsombor Zrubka, Zsuzsanna Beretzky, Zoltán Hermann, Valentin Brodszky, László Gulácsi, Fanni Rencz, Petra Baji, Dominik Golicki, Valentina Prevolnik-Rupel, Márta Péntek. A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases. The European Journal of Health Economics 2019; 20(S1): 119 doi: 10.1007/s10198-019-01069-8
|
4 |
E Joline de Groof, Toer W Stevens, Emma J Eshuis, Tjibbe J Gardenbroek, Judith E Bosmans, JM van Dongen, Bregje Mol, Christianne J Buskens, Pieter C F Stokkers, Ailsa Hart, Geert R D’Haens, Willem A Bemelman, Cyriel Y Ponsioen. Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn’s disease: the LIR!C Trial. Gut 2019; 68(10): 1774 doi: 10.1136/gutjnl-2018-317539
|
5 |
Byong Duk Ye, Marina Pesegova, Olga Alexeeva, Marina Osipenko, Adi Lahat, Andriy Dorofeyev, Sigal Fishman, Olena Levchenko, Jae Hee Cheon, Maria Lia Scribano, Radu-Bogdan Mateescu, Kang-Moon Lee, Chang Soo Eun, Sang Joon Lee, Sung Young Lee, HoUng Kim, Stefan Schreiber, Heather Fowler, Raymond Cheung, Young-Ho Kim. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. The Lancet 2019; 393(10182): 1699 doi: 10.1016/S0140-6736(18)32196-2
|
6 |
Teodora Spataru, Remus Popescu, Monica State, Mihai Pahomeanu, Bogdan Mateescu, Lucian Negreanu. The Efficacy, Safety, and Persistence of Therapy after Non-Medical Switching from an Originator Adalimumab in Inflammatory Bowel Disease: Real-Life Experience from Two Tertiary Centres. Pharmaceuticals 2024; 17(10): 1319 doi: 10.3390/ph17101319
|
7 |
Manuel Barreiro-de Acosta, Alberto Molero, Esther Artime, Silvia Díaz-Cerezo, Luis Lizán, Héctor David de Paz, María Dolores Martín-Arranz. Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn’s disease) in Spain: A Systematic Review. Advances in Therapy 2023; 40(5): 1975 doi: 10.1007/s12325-023-02473-6
|
8 |
Biljana Tubic, Vanda Marković-Peković, Saša Jungić, Eleonora Allocati, Brian Godman. Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications. Medicine Access @ Point of Care 2021; 5 doi: 10.1177/23992026211027692
|
9 |
Raffaella Franca, Debora Curci, Marianna Lucafò, Giuliana Decorti, Gabriele Stocco. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. Expert Opinion on Drug Metabolism & Toxicology 2019; 15(7): 527 doi: 10.1080/17425255.2019.1630378
|
10 |
Gregory Reardon. Biologics, Biosimilars, and Biobetters. 2020; : 195 doi: 10.1002/9781119564690.ch12
|
11 |
Karoline Anisdahl, Sandre Svatun Lirhus, Asle W. Medhus, Bjørn Moum, Hans Olav Melberg, Marte Lie Høivik. First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study. Scandinavian Journal of Gastroenterology 2021; 56(10): 1163 doi: 10.1080/00365521.2021.1955147
|
12 |
Rotraut Mössner. Biosimilars and patient care. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2018; 16(2): 133 doi: 10.1111/ddg.13429
|
13 |
Guozhi Wu, Yuan Yang, Min Liu, Yuping Wang, Qinghong Guo. Systematic Review and Network Meta-Analysis: Comparative Efficacy and Safety of Biosimilars, Biologics and JAK1 Inhibitors for Active Crohn Disease. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.655865
|
14 |
Lynn Huynh, Steve Hass, Laurent Peyrin-Biroulet, Mei Sheng Duh, Heather Sipsma, Mu Cheng, Angie Lax, Arpita Nag. Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe. Crohn's & Colitis 360 2022; 4(1) doi: 10.1093/crocol/otac001
|
15 |
Fanni Rencz, Peep F. M. Stalmeier, Márta Péntek, Valentin Brodszky, Gábor Ruzsa, Lóránt Gönczi, Károly Palatka, László Herszényi, Eszter Schäfer, János Banai, Mariann Rutka, László Gulácsi, Peter L. Lakatos. Patient and general population values for luminal and perianal fistulising Crohn’s disease health states. The European Journal of Health Economics 2019; 20(S1): 91 doi: 10.1007/s10198-019-01065-y
|
16 |
María Chaparro, María G. Donday, Manuel Barreiro-de Acosta, Eugeni Domènech, María Esteve, Valle García-Sánchez, Pilar Nos, Julián Panés, Concepción Martínez, Javier P. Gisbert, F. Abad, M. Aguas Peris, E. Agüero Tejado, C. Alba, M. Albert, H. Alemán, A. Algaba, I. Alonso Abreu, M.P. Amador, M. Amat, T. Angueira, C. Arajol, L. Arias-González, A. Arrondo Velasco, M. Baldán, B. Bardán García, A. Bargalló García, M. Barreiro de Acosta, J. Barrio Andrés, G. Bastida Paz, I. Bastón Rey, L. Batista, M. Bellver Martínez, B. Beltrán Niclós, J.M. Benítez, Y. Ber Nieto, F. Bermejo, D. Bernardo, I. Blázquez Gómez, A. Bouhmidi Assakali, D. Busquets Casals, J.L. Cabriada Nuño, X. Calvet Calvo, M.V. Calvo Hernández, M. Calvo, B. Camps, A.Y. Carbajo, G. Cardona Peitx, T. Caro-Patón, M. Carrillo Palau, S. Carrión Bolorino, M.J. Casanova, J.A. Casellas Valdé, A. Castaño García, B. Castro Senosiain, D. Ceballos, E. Cerrillo, S. Chacón Martínez, F. Consuelo Cañete Pizarro, M.L. de Castro Parga, M. de Miguel, R. de Francisco García, M.D. de la Cruz Ramírez, J. del Hoyo Francisco, P. Delgado Guillena, T. Desongles Corrales, A. Echarri Piudo, E. Espino Paisan, M. Espona Quer, A. Fernández Pordomingo, J.L. Fernández Forcelledo, S. Fernández-Tomé, R. Ferreiro Iglesias, I. Ferrer Bradley, A. Ferrer, A. Figueroa, M. Gallach Montero, P. García Iglesias, C. García García-Lezcún, L. García Ramírez, M.J. García García, O. García-Bosh, A. Garre, T. Giménez Poderós, L. Gómez Irwin, B. Gómez Pastrana, E. Gómez Delgado, Y. González Lama, Á. Gracia García, B. Gracia García, J. Guardiola, I. Guerra, E. Guerra, V. Guillot, S. Gustmancher Saiz, A. Gutiérrez Casbas, V. Hernández Ramírez, M.M. Hernando Verdugo, B. Hernández Muniesa, R. Hernanz Chaves, J.M. Herrera Justiniano, J Hinojosa del Val, S Ibáñez Feijoo, M Iborra Colomino, E Iglesias Flores, E. Izquierdo García, M J Sampedro González, A J. Lucendo, N Jiménez García, E. Leo Carnerero, I. Loizaga Díaz, A López de Torre Querejazu, P López Sánchez, J Luis Parras, M Maia Boscá, M Mañosa, S Marín Pedrosa, A Marín, Á Marinero, I Marín-Jiménez, L Márquez Mosquera, JL Márquez Galán, E Martín Arranz, MD Martín Arranz, J Martínez Cadilla, JM Martínez Sesmero, B Martínez Sánchez, V Matallana, MI Mateos Hernández, AG McNicholl, R Mejuto Fernández, L Melcarne, L Menchén, J Méndez-Castrillón Rodríguez, O Merino Ochoa, M Mínguez, G Molas Ferrer, M Montoro Huguet, A Montserrat Torres, F Mora, I Moraleja Yudego, VJ Morales Alvarado, L Morales Martínez, A Morell, C Motos García, F Muñoz Alonso, MC Muñoz Villafranca, JE Muñoz, A Mur, Ó Nantes, P Navarro, M Navarro- Llavat, P Nos Mateu, A Núñez Alonso, A Núñez Ortiz, D Olivares, V Ollero Pena, J Orobitg, L Ortega, J Ortiz de Zárate, H Pallarés Manrique, A Paradela Carreiro, L Peral Ballester, S Pereira Bueno, I Pérez Martínez, JR Pineda Mariño, C Piñero Pérez, A Planas Giner, MR Plaza Santos, Á Ponferrada Díaz, J Poza Cardón, V Prieto Vicente, L Puchades, L Ramos López, S Redondo, S Riestra Menéndez, M Rivero Tirado, I Rodríguez Lago, C Rodríguez Gutiérrez, E Rodríguez, S Romero Izquierdo, S Rubio Iturria, MB Ruiz Antorán, A Ruiz, LF Salazar, A Sánchez Ulayar, E Sánchez Gómez, C Sánchez, C Sangrador, K Serra, K Spicakova, C Suárez Ferrer, A Talavera Fabuel, C Taxonera, M Tordera, E Torrella Cortés, J Tosca, C Trigo Salado, F Uriarte Estefanía, M Van Domselaar, JM Vázquez Morón, P Ventura López, M Vera, M Vicuña Arregui, A Villoria Ferrer, T Virgós Aller, D Yáñez Feria. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial. Therapeutic Advances in Gastroenterology 2019; 12 doi: 10.1177/1756284819874202
|
17 |
Karim Sariahmed, Joshua Kurian, Anjani K. Singh, Christopher Leyton, Aurelia Minuti, Elina Jerschow, Shitij Arora, Sunit P. Jariwala. Social, political, and economic determinants of access to biologics: A scoping review of structural determinants in the clinical disparities literature. Research in Social and Administrative Pharmacy 2022; 18(12): 4038 doi: 10.1016/j.sapharm.2022.07.047
|
18 |
Aditi Kumar, Nuha Yassin, Alexandra Marley, Vittoria Bellato, Caterina Foppa, Gianluca Pellino, Pär Myrelid, Monica Millan, Beatriz Gros, Nicolas Avellaneda, Ignacio Catalan-Serra, Alaa El-Hussuna, João A. Cunha Neves, Joana Roseira, Miguel F. Cunha, Bram Verstockt, Dominik Bettenworth, Diane Mege, Matthew J. Brookes. Crossing barriers: the burden of inflammatory bowel disease across Western Europe. Therapeutic Advances in Gastroenterology 2023; 16 doi: 10.1177/17562848231218615
|
19 |
Daniel C. Baumgart, Laurent Misery, Sue Naeyaert, Peter C. Taylor. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. Frontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.00279
|
20 |
Johan Burisch, Jennifer Claytor, Inmaculada Hernandez, Jason Ken Hou, Gilaad G. Kaplan. The Cost of Inflammatory Bowel Disease Care – How to Make it Sustainable. Clinical Gastroenterology and Hepatology 2024; doi: 10.1016/j.cgh.2024.06.049
|
21 |
Beate Beyer, Nicole Walch, Alois Jungbauer, Nico Lingg. How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity. Biotechnology Journal 2019; 14(4) doi: 10.1002/biot.201800340
|
22 |
Qin Xiong, Fuyou Tang, Yilin Li, Fengjiao Xie, Lei Yuan, Chengjiao Yao, Ruike Wu, Juan Wang, Qiuxiang Wang, Peimin Feng. Association of inflammatory bowel disease with suicidal ideation, suicide attempts, and suicide: A systematic review and meta-analysis. Journal of Psychosomatic Research 2022; 160: 110983 doi: 10.1016/j.jpsychores.2022.110983
|
23 |
Fanni Rencz, Peter L. Lakatos, László Gulácsi, Valentin Brodszky, Zsuzsanna Kürti, Szilvia Lovas, János Banai, László Herszényi, Tamás Cserni, Tamás Molnár, Márta Péntek, Károly Palatka. Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s disease. Quality of Life Research 2019; 28(1): 141 doi: 10.1007/s11136-018-2003-4
|
24 |
Klaus Herrlinger, Eduard F. Stange. Therapie-Update Morbus Crohn 2021. Gastro-News 2021; 8(5): 26 doi: 10.1007/s15036-021-2391-0
|
25 |
Brian Godman, Magdalene Wladysiuk, Stuart McTaggart, Amanj Kurdi, Eleonora Allocati, Mihajlo Jakovljevic, Francis Kalemeera, Iris Hoxha, Anna Nachtnebel, Robert Sauermann, Manfred Hinteregger, Vanda Marković-Peković, Biljana Tubic, Guenka Petrova, Konstantin Tachkov, Juraj Slabý, Radka Nejezchlebova, Iva Selke Krulichová, Ott Laius, Gisbert Selke, Irene Langner, András Harsanyi, András Inotai, Arianit Jakupi, Svens Henkuzens, Kristina Garuolienė, Jolanta Gulbinovič, Patricia Vella Bonanno, Jakub Rutkowski, Skule Ingeberg, Øyvind Melien, Ileana Mardare, Jurij Fürst, Sean MacBride-Stewart, Carol Holmes, Caridad Pontes, Corinne Zara, Marta Turu Pedrola, Mikael Hoffmann, Vasileios Kourafalos, Alice Pisana, Rita Banzi, Stephen Campbell, Bjorn Wettermark, Kumud Kafle. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. BioMed Research International 2021; 2021: 1 doi: 10.1155/2021/9996193
|
26 |
Mourad F. Rezk, Burkhard Pieper. Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review. Advances in Therapy 2020; 37(9): 3732 doi: 10.1007/s12325-020-01437-4
|
27 |
Rotraut Mössner. Biosimilars und Patientenversorgung. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2018; 16(2): 133 doi: 10.1111/ddg.13429_g
|
28 |
Przemysław Holko, Paweł Kawalec, Andrzej Pilc. Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist. PharmacoEconomics 2018; 36(7): 853 doi: 10.1007/s40273-018-0653-2
|
29 |
C.R.H. Hedin, E. Sonkoly, M. Eberhardson, M. Ståhle. Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach. Journal of Internal Medicine 2021; 290(2): 257 doi: 10.1111/joim.13282
|
30 |
Fernando de Mora. Biosimilars: A Value Proposition. BioDrugs 2019; 33(4): 353 doi: 10.1007/s40259-019-00360-7
|
31 |
Simona Di Caro, Konstantinos C. Fragkos, Katie Keetarut, Hui Fen Koo, Gregory Sebepos-Rogers, Hajeena Saravanapavan, John Barragry, Jennifer Rogers, Shameer J. Mehta, Farooq Rahman. Enteral Nutrition in Adult Crohn’s Disease: Toward a Paradigm Shift. Nutrients 2019; 11(9): 2222 doi: 10.3390/nu11092222
|
32 |
Jan Marsal, Manuel Barreiro-de Acosta, Irina Blumenstein, Maria Cappello, Thomas Bazin, Shaji Sebastian. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.897936
|
33 |
Halina Cichoż-Lach, Agata Michalak, Maria Kopertowska-Majchrzak, Piotr Eder, Kamila Stawczyk-Eder, Katarzyna Waszak, Renata Talar-Wojnarowska, Hubert Zatorski, Anna Solarska-Półchłopek, Jarosław Chmielnicki, Rafał Filip, Anna Pękala, Maria Janiak, Krzysztof Skrobot, Ewa Kasińska, Michał Krogulecki, Piotr Królikowski, Maria Kłopocka, Ariel Liebert, Elżbieta Poniewierka, Izabela Smoła, Anita Gąsiorowska, Aleksandra Kaczka, Joanna Wypych, Krzysztof Wojciechowski, Szymon Drygała, Edyta Zagórowicz. Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). Therapeutic Advances in Gastroenterology 2021; 14 doi: 10.1177/17562848211036456
|
34 |
Christopher J. Edwards, Jana Hercogová, Helene Albrand, Aurelian Amiot. Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. Expert Opinion on Biological Therapy 2019; 19(10): 1001 doi: 10.1080/14712598.2019.1610381
|
35 |
Cristina Bezzio, Nicola Imperatore, Alessandro Armuzzi, Fernando Rizzello, Gianpiero Manes, Fabrizio Bossa, Emma Calabrese, Flavio Caprioli, Marco Daperno, Filippo Mocciaro, Ambrogio Orlando, Claudio Papi, Antonio Rispo, Simone Saibeni. Barriers to anti‐TNFalpha prescription among Italian physicians managing inflammatory bowel disease. GastroHep 2019; 1(3): 93 doi: 10.1002/ygh2.331
|